Stefan Merlo, Vice President, Commercial Development, CSL Seqirus discusses how COVID-19 has evolved the discussion of vaccines and the long-term concerns stemming from flu vaccine fatigue.
At Pharma 2023 in Barcelona, Stefan Merlo, Vice President, Commercial Development at CSL Seqirus, discussed the global vaccine journey, the connected customer experience and the role of consumer and government education to improve public health.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.